11/15
09:30 am
tsha
Rating for TSHA
High
Report
Rating for TSHA
11/14
06:30 pm
tsha
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $7.00 price target on the stock.
Medium
Report
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $7.00 price target on the stock.
11/14
05:40 pm
tsha
Rating for TSHA
Medium
Report
Rating for TSHA
11/14
01:43 pm
tsha
Rating for TSHA
Medium
Report
Rating for TSHA
11/14
01:43 pm
tsha
Rating for TSHA
Medium
Report
Rating for TSHA
11/14
08:59 am
tsha
Rating for TSHA
High
Report
Rating for TSHA
11/12
11:07 am
tsha
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $5.00 price target on the stock.
High
Report
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $5.00 price target on the stock.
11/12
11:07 am
tsha
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $5.00 price target on the stock.
High
Report
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $5.00 price target on the stock.
11/12
10:52 am
tsha
Rating for TSHA
High
Report
Rating for TSHA
11/12
10:52 am
tsha
Rating for TSHA
High
Report
Rating for TSHA
11/12
09:03 am
tsha
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $7.00 price target on the stock.
High
Report
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $7.00 price target on the stock.
11/12
08:39 am
tsha
Rating for TSHA
High
Report
Rating for TSHA
11/12
08:33 am
tsha
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $6.00 price target on the stock.
High
Report
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $6.00 price target on the stock.
11/12
06:19 am
tsha
Rating for TSHA
High
Report
Rating for TSHA
11/12
06:19 am
tsha
Rating for TSHA
High
Report
Rating for TSHA